LUNGevity Foundation· @LUNGevity · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
Jonathan W. Riess, MD, of
@UCD_Cancer
presents data on first-in-class RAS(ON) G12D inhibitor in #NSCLC at #AACR26. Zoldonrasib (RMC-9805) targets ACTIVE GTP-bound state of KRAS G12D, mutation affecting approx. 61,000 new US patients/year w/ no approved targeted therapy.
Key
Heat 25 · 18 likes · 1 reply · 6 reposts
Source: LUNGevity Foundation · x.com